Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-derived resources for decoding and targeting brain metastases ecosystems.

EMBO molecular medicine·2026

Same author

Integrated transcriptomic and TCR profiling reveals local immune dysregulation of T cells in Gl aGvHD.

Bone marrow transplantation·2026

Same author

Tumor-infiltrating CD8<sup>+</sup>Ki-67<sup>+</sup> and CD8<sup>+</sup>LAG-3<sup>+</sup> T cells are associated with improved patient survival in retroperitoneal dedifferentiated liposarcomas and leiomyosarcomas.

Experimental and molecular pathology·2026

Same author

Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.

Journal of translational medicine·2025

Same author

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Blood·2025

Same author

Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer.

iScience·2025

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Dendritic cell-based immunotherapy for prostate cancer.

Hanka Jähnisch¹, Susanne Füssel, Andrea Kiessling

¹Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstrasse 74, Dresden, Germany.

Clinical & Developmental Immunology

|November 16, 2010

Summary

This summary is machine-generated.

Dendritic cell (DC) vaccines show promise for prostate cancer. Sipuleucel-T, a DC-based immunotherapy, improved survival in metastatic castration-resistant prostate cancer patients and is FDA-approved.

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jun 6, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

Immunology
Oncology
Vaccinology

Background:

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) crucial for initiating and regulating T-cell responses.
DC-based cancer vaccination strategies offer a promising therapeutic avenue.
Prostate cancer remains a significant health concern, necessitating novel treatment approaches.

Purpose of the Study:

To evaluate the safety and efficacy of DC-based immunotherapeutic strategies in prostate cancer patients.
To assess the impact of sipuleucel-T on immunological and clinical responses.
To determine the overall survival benefit of sipuleucel-T in metastatic castration-resistant prostate cancer.

Main Methods:

Clinical trials were conducted involving prostate cancer patients.
DCs were loaded ex vivo with tumor-associated antigens.
Sipuleucel-T, comprising autologous PBMCs exposed to the fusion protein PA2024, was administered.

Main Results:

DC-based immunotherapies were found to be safe and feasible in prostate cancer patients.
These strategies successfully induced immunological and clinical responses.
Sipuleucel-T administration led to prolonged overall survival in patients with metastatic castration-resistant prostate cancer.

Conclusions:

DC-based vaccination is a safe and feasible approach for prostate cancer immunotherapy.
Sipuleucel-T demonstrated a survival benefit for patients with metastatic castration-resistant prostate cancer.
The FDA approval of sipuleucel-T in 2010 marked a significant advancement in prostate cancer treatment.